On-Demand CGT Formulation Webinars
-
Democratizing RNA Nanotherapeutics
4/14/2022
This webinar is presented by Dr. John P. Cooke, Chair of the Department of Cardiovascular Sciences at the Houston Methodist Research Institute, Director of the Center for Cardiovascular Regeneration, and Medical Director of the RNA Therapeutics Program in the Houston Methodist DeBakey Heart and Vascular Center.
-
Polysarcosine-Functionalized LNPs For Therapeutic mRNA Delivery
4/14/2022
Discover how polysarcosine-functionalized lipid nanoparticles are transforming mRNA delivery. Join Dr. Heinrich Haas of BioNTech as he unveils innovative research and its implications for therapeutic breakthroughs.
-
RNA Vaccine Development To Phase I
4/14/2022
Dr. John Lewis, Founder and CEO, Entos Pharmaceuticals, presents RNA Vaccine Development to Phase I.
-
DNA Vaccine Development In A Global Pandemic: A Personal Account
4/14/2022
Dr. Gerrit Borchard, University of Geneva, presents a personal account of DNA vaccine development in a global pandemic.
-
Scale Up And Manufacturing Of RNA-LNPs For A COVID-19 Vaccine
4/13/2022
Dr. Jason Coleman, Clinical Application Scientist Lead with Precision NanoSystems, presents on an overview of the development and scale-up activities needed to progress this saRNA vaccine to the clinic.
-
Molecular And Colloidal Ionization Properties Of Lipid Nanoparticle mRNA Vaccines
4/13/2022
Dr. Michael Buschmann, George Mason University, presents an overview of molecular and colloidal ionization properties of lipid nanoparticle mRNA vaccines.
-
Strategies For Scaling Up mRNA Manufacturing
4/11/2022
The clinical promise of mRNA therapeutics and vaccines is clear, but compared to monoclonal antibodies or viral vectors, their novelty also brings new challenges to the manufacturing process.
-
Measuring Physical Properties Of Liposomes And LNPs For RNA Delivery With MD-AF4
2/7/2022
This webinar presents examples of how MD-AF4 quantifies key quality attributes of complex nanomedicine formulations such as particle size distributions, shape, concentration and stability, using the SOP guidelines.
-
LNP-RNA Therapeutics: Size, Concentration, Payload, And Quality With Light Scattering
1/30/2022
In this webinar we review a method for characterizing and quantifying lipid nanoparticle formualtions for nucleic acid therapeutics. The method quantifies LNP size, concentration and other quality attributes.
-
Addressing Industry Challenges In mRNA Product Commercialization
While the speed of production and flexibility of mRNA are appealing, several industry challenges must still be addressed to realize the full potential and further expand its use.